CTSO

Cytosorbents Corporation

$5.34

-7.93%
SectorHealthcareIndustryMedical DevicesCountryUnited States

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications.

Source: Yahoo Finance
AI summary

Price & performance

1M-13.7%
3M-31.1%
YTD-62.2%
1Y-72.0%
52-week range—
Beta0.75
Full chart and returns against a benchmark

Q-Score

35/ 100

Quality against peers; 50 is the peer median.

Growth33
Risk44
Performance31
Valuation44
Profitability49
Leverage20
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$37.1M+4.1%
Net income-$8.2M
Net margin-22.1%+36.1 pts
Historical fundamentals

Red flags in filings

4active red flags
Going-concern doubtMar 30, 2026
Material weakness in controlsMar 30, 2026
Restated financialsMar 31, 2025
Filings, findings and the timeline

Revenue exposure

Regions, segments, customers and suppliers

Valuation

CTSOIndustryP/E—29.61P/S0.453.49EV/EBITDA—18.38P/B—3.39PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 12next report, after the close
EPS estimate—
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate